Lori Hazlehurst

5.9k total citations · 1 hit paper
91 papers, 4.6k citations indexed

About

Lori Hazlehurst is a scholar working on Molecular Biology, Hematology and Oncology. According to data from OpenAlex, Lori Hazlehurst has authored 91 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Molecular Biology, 44 papers in Hematology and 36 papers in Oncology. Recurrent topics in Lori Hazlehurst's work include Multiple Myeloma Research and Treatments (29 papers), Cell Adhesion Molecules Research (12 papers) and Cancer therapeutics and mechanisms (11 papers). Lori Hazlehurst is often cited by papers focused on Multiple Myeloma Research and Treatments (29 papers), Cell Adhesion Molecules Research (12 papers) and Cancer therapeutics and mechanisms (11 papers). Lori Hazlehurst collaborates with scholars based in United States, Japan and France. Lori Hazlehurst's co-authors include William S. Dalton, William S. Dalton, Jason S. Damiano, Anne E. Cress, Mark B. Meads, Аlexander А. Shtil, Rajesh R. Nair, David Boulware, Michael F. Emmons and Terry H. Landowski and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Lori Hazlehurst

88 papers receiving 4.5k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines

1999 718 citations Anne E. Cress, Lori Hazlehurst et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lori Hazlehurst United States	35	2.5k	1.9k	1.7k	575	557	91	4.6k
Ellen Weisberg United States	40	3.7k 1.5×	1.5k 0.8×	2.9k 1.7×	453 0.8×	412 0.7×	99	6.6k
Peter Blume‐Jensen United States	18	3.3k 1.3×	1.3k 0.7×	488 0.3×	840 1.5×	454 0.8×	25	5.0k
Terry H. Landowski United States	22	1.9k 0.8×	1.7k 0.9×	772 0.5×	821 1.4×	511 0.9×	43	3.4k
Emma Shtivelman United States	33	2.4k 1.0×	931 0.5×	1.4k 0.8×	287 0.5×	602 1.1×	42	4.2k
Marc S. Raab Germany	38	3.4k 1.3×	2.4k 1.3×	3.5k 2.1×	736 1.3×	297 0.5×	201	5.5k
Suzanne Trudel Canada	40	3.4k 1.4×	2.3k 1.2×	3.0k 1.8×	560 1.0×	334 0.6×	248	5.2k
Ruben D. Carrasco United States	26	2.4k 1.0×	1.3k 0.7×	1.2k 0.7×	889 1.5×	568 1.0×	64	3.8k
Joel Johansson United States	34	4.3k 1.7×	1.8k 0.9×	1.1k 0.7×	739 1.3×	512 0.9×	93	6.0k
Laura K. Shawver United States	26	3.4k 1.4×	2.0k 1.0×	317 0.2×	363 0.6×	1.2k 2.1×	47	5.1k
Stefan Hemmerich United States	30	2.3k 0.9×	650 0.3×	870 0.5×	1.2k 2.1×	566 1.0×	44	4.4k

Countries citing papers authored by Lori Hazlehurst

Since Specialization

Citations

This map shows the geographic impact of Lori Hazlehurst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lori Hazlehurst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lori Hazlehurst more than expected).

Fields of papers citing papers by Lori Hazlehurst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lori Hazlehurst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lori Hazlehurst. The network helps show where Lori Hazlehurst may publish in the future.

Co-authorship network of co-authors of Lori Hazlehurst

This figure shows the co-authorship network connecting the top 25 collaborators of Lori Hazlehurst. A scholar is included among the top collaborators of Lori Hazlehurst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lori Hazlehurst. Lori Hazlehurst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Li, Lin, Maciej Kmieciak, L. Ashley Cowart, et al.. (2025). Src inhibition potentiates MCL-1 antagonist activity in acute myeloid leukemia. Signal Transduction and Targeted Therapy. 10(1). 50–50. 3 indexed citations

Khushalani, Nikhil I., Ghassan El‐Haddad, Kenneth L. Gage, et al.. (2024). First-in-human study of ²²⁵actinium mti-201 (²²⁵Ac-MTI-201) in metastatic uveal melanoma (UM).. Journal of Clinical Oncology. 42(16_suppl). TPS9612–TPS9612. 1 indexed citations

Khushalani, Nikhil I., Ghassan El‐Haddad, Kenneth L. Gage, et al.. (2024). 1128P Preliminary results of first-in-human study of 225-Actinium MTI-201 (225Ac-MTI-201) in metastatic uveal melanoma. Annals of Oncology. 35. S742–S742. 1 indexed citations

Malla, Midhun, Sachin Kumar Deshmukh, Sharon Wu, et al.. (2024). Mesothelin expression correlates with elevated inhibitory immune activity in patients with colorectal cancer. Cancer Gene Therapy. 31(10). 1547–1558. 6 indexed citations

Gard, Jaime M.C., Charles W. Wolgemuth, Beatrice S. Knudsen, et al.. (2023). Biophysical phenotype mixtures reveal advantages for tumor muscle invasion in vivo. Biophysical Journal. 122(21). 4194–4206. 2 indexed citations

Murthy, Pranav, Michael T. Lotze, Herbert J. Zeh, et al.. (2023). Chloroquine reduces neutrophil extracellular trap (NET) formation through inhibition of peptidyl arginine deiminase 4 (PAD4). Clinical & Experimental Immunology. 211(3). 239–247. 23 indexed citations

Menze, Michael A., Timothy E. Long, Lori Hazlehurst, et al.. (2023). Development of a fluorescence screening assay for binding partners of the iron-sulfur mitochondrial protein mitoNEET. Bioorganic & Medicinal Chemistry Letters. 89. 129310–129310.

Wang, Lei, et al.. (2023). Inflammatory Bone Marrow Mesenchymal Stem Cells in Multiple Myeloma: Transcriptional Signature and In Vitro Modeling. Cancers. 15(21). 5148–5148. 6 indexed citations

Hayes, Karen E., et al.. (2022). Identification of Natural Product Sulfuretin Derivatives as Inhibitors for the Endoplasmic Reticulum Redox Protein ERO1α. PubMed. 2(2). 161–170. 6 indexed citations

10.

Saralkar, Pushkar, Alexander Mdzinarishvili, Tasneem Arsiwala, et al.. (2021). The Mitochondrial mitoNEET Ligand NL-1 Is Protective in a Murine Model of Transient Cerebral Ischemic Stroke. Pharmaceutical Research. 38(5). 803–817. 10 indexed citations

11.

Caulfield, Thomas R., Karen E. Hayes, Joon Seok Oh, et al.. (2020). A Virtual Screening Platform Identifies Chloroethylagelastatin A as a Potential Ribosomal Inhibitor. Biomolecules. 10(10). 1407–1407. 3 indexed citations

12.

Li, Xiuling, Lori Hazlehurst, Pablo Martínez-Acedo, et al.. (2017). Stable and Potent Selenomab-Drug Conjugates. Cell chemical biology. 24(4). 433–442.e6. 33 indexed citations

13.

Meads, Mark B., Bin Fang, Linda Mathews, et al.. (2015). Targeting PYK2 mediates microenvironment-specific cell death in multiple myeloma. Oncogene. 35(21). 2723–2734. 33 indexed citations

14.

Jain, Priyesh, Rajesh R. Nair, Michael F. Emmons, et al.. (2013). MTI-101 (Cyclized HYD1) Binds a CD44 Containing Complex and Induces Necrotic Cell Death in Multiple Myeloma. Molecular Cancer Therapeutics. 12(11). 2446–2458. 21 indexed citations

15.

Ribeiro, Maria L.C., Timothy Jacobson, Lori Hazlehurst, et al.. (2013). A Preclinical Assay for Chemosensitivity in Multiple Myeloma. Cancer Research. 74(1). 56–67. 42 indexed citations

16.

Shain, Kenneth H., et al.. (2012). Personalizing Myeloma Chemotherapy Using Evolutionary Computational Models and Ex Vivo Assays.. Blood. 120(21). 2960–2960. 2 indexed citations

17.

Emmons, Michael F., Rajesh R. Nair, Rachid Baz, et al.. (2011). Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype. Molecular Cancer Therapeutics. 10(12). 2257–2266. 24 indexed citations

18.

Nair, Rajesh R., Michael F. Emmons, Anne E. Cress, et al.. (2009). HYD1-induced increase in reactive oxygen species leads to autophagy and necrotic cell death in multiple myeloma cells. Molecular Cancer Therapeutics. 8(8). 2441–2451. 33 indexed citations

19.

Yarde, Danielle N., Vasco Oliveira, Linda Mathews, et al.. (2009). Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple Myeloma. Cancer Research. 69(24). 9367–9375. 90 indexed citations

20.

Nair, Rajesh R., et al.. (2008). Bone marrow stromal cells activate Stat3 and confer resistance to Bcr-Abl inhibitors in K562 CML cells. Cancer Research. 68. 2454–2454.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact